Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 241

1.

Proteasome inhibition attenuates heart failure during the late stages of pressure overload through alterations in collagen expression.

Ma Y, Chen Y, Yang Y, Chen B, Liu D, Xiong Z, Zhang C, Dong Y.

Biochem Pharmacol. 2013 Jan 15;85(2):223-33. doi: 10.1016/j.bcp.2012.10.025. Epub 2012 Nov 8.

PMID:
23142711
2.

MG132 treatment attenuates cardiac remodeling and dysfunction following aortic banding in rats via the NF-κB/TGFβ1 pathway.

Ma Y, Chen B, Liu D, Yang Y, Xiong Z, Zeng J, Dong Y.

Biochem Pharmacol. 2011 May 15;81(10):1228-36. doi: 10.1016/j.bcp.2011.03.009. Epub 2011 Mar 21.

PMID:
21420391
3.

Adapter molecule DOC-2 is differentially expressed in pressure and volume overload hypertrophy and inhibits collagen synthesis in cardiac fibroblasts.

Kumbar DH, VanBergen A, Ocampo C, Muangmingsuk S, Griffin AJ, Gupta M.

J Appl Physiol (1985). 2007 May;102(5):2024-32. Epub 2007 Jan 25.

4.

Metformin attenuates cardiac fibrosis by inhibiting the TGFbeta1-Smad3 signalling pathway.

Xiao H, Ma X, Feng W, Fu Y, Lu Z, Xu M, Shen Q, Zhu Y, Zhang Y.

Cardiovasc Res. 2010 Aug 1;87(3):504-13. doi: 10.1093/cvr/cvq066. Epub 2010 Mar 3.

5.

MG132, a proteasome inhibitor, attenuates pressure-overload-induced cardiac hypertrophy in rats by modulation of mitogen-activated protein kinase signals.

Chen B, Ma Y, Meng R, Xiong Z, Zhang C, Chen G, Zhang A, Dong Y.

Acta Biochim Biophys Sin (Shanghai). 2010 Apr;42(4):253-8.

6.

K(ATP) activation prevents progression of cardiac hypertrophy to failure induced by pressure overload via protecting endothelial function.

Gao S, Long CL, Wang RH, Wang H.

Cardiovasc Res. 2009 Aug 1;83(3):444-56. doi: 10.1093/cvr/cvp099. Epub 2009 Mar 20.

7.

Chronic administration of angiotensin-(1-7) attenuates pressure-overload left ventricular hypertrophy and fibrosis in rats.

Wang LJ, He JG, Ma H, Cai YM, Liao XX, Zeng WT, Liu J, Wang LC.

Di Yi Jun Yi Da Xue Xue Bao. 2005 May;25(5):481-7.

8.

Chronic administration of hexarelin attenuates cardiac fibrosis in the spontaneously hypertensive rat.

Xu X, Ding F, Pang J, Gao X, Xu RK, Hao W, Cao JM, Chen C.

Am J Physiol Heart Circ Physiol. 2012 Sep 15;303(6):H703-11. doi: 10.1152/ajpheart.00257.2011. Epub 2012 Jul 27.

9.

Effects of a Rho kinase inhibitor on pressure overload induced cardiac hypertrophy and associated diastolic dysfunction.

Phrommintikul A, Tran L, Kompa A, Wang B, Adrahtas A, Cantwell D, Kelly DJ, Krum H.

Am J Physiol Heart Circ Physiol. 2008 Apr;294(4):H1804-14. doi: 10.1152/ajpheart.01078.2007. Epub 2008 Feb 1.

10.

[Spironolactone: renaissance of anti-aldosterone therapy in heart failure?].

Brilla CG, Schencking M, Scheer C, Rupp H.

Praxis (Bern 1994). 1997 Apr 2;86(14):566-74. Review. German.

PMID:
9198851
11.

Angiotensin (1-7) prevent heart dysfunction and left ventricular remodeling caused by renal dysfunction in 5/6 nephrectomy mice.

Li Y, Wu J, He Q, Shou Z, Zhang P, Pen W, Zhu Y, Chen J.

Hypertens Res. 2009 May;32(5):369-74. doi: 10.1038/hr.2009.25. Epub 2009 Mar 27.

PMID:
19325560
12.

Allicin ameliorates cardiac hypertrophy and fibrosis through enhancing of Nrf2 antioxidant signaling pathways.

Li XH, Li CY, Xiang ZG, Hu JJ, Lu JM, Tian RB, Jia W.

Cardiovasc Drugs Ther. 2012 Dec;26(6):457-65. doi: 10.1007/s10557-012-6415-z.

PMID:
22990325
13.

Oxidative stress mediates cardiac fibrosis by enhancing transforming growth factor-beta1 in hypertensive rats.

Zhao W, Zhao T, Chen Y, Ahokas RA, Sun Y.

Mol Cell Biochem. 2008 Oct;317(1-2):43-50. doi: 10.1007/s11010-008-9803-8. Epub 2008 Jun 26.

PMID:
18581202
14.

Role of aldosterone in angiotensin II-induced cardiac and aortic inflammation, fibrosis, and hypertrophy.

Neves MF, Amiri F, Virdis A, Diep QN, Schiffrin EL; CIHR Multidisciplinary Research Group on Hypertension.

Can J Physiol Pharmacol. 2005 Nov;83(11):999-1006.

PMID:
16391708
15.

The cardiac structure-function relationship and the renin-angiotensin-aldosterone system in hypertension and heart failure.

Brilla CG.

Curr Opin Cardiol. 1994 Jul;9 Suppl 1:S2-10; discussion S10-1. Review.

PMID:
7827369
16.

Proteasome inhibition decreases cardiac remodeling after initiation of pressure overload.

Hedhli N, Lizano P, Hong C, Fritzky LF, Dhar SK, Liu H, Tian Y, Gao S, Madura K, Vatner SF, Depre C.

Am J Physiol Heart Circ Physiol. 2008 Oct;295(4):H1385-93. doi: 10.1152/ajpheart.00532.2008. Epub 2008 Aug 1.

17.

Chymase inhibition prevents cardiac fibrosis and improves diastolic dysfunction in the progression of heart failure.

Matsumoto T, Wada A, Tsutamoto T, Ohnishi M, Isono T, Kinoshita M.

Circulation. 2003 May 27;107(20):2555-8. Epub 2003 May 12.

18.

Modification of cardiac subcellular remodeling due to pressure overload by captopril and losartan.

Liu X, Sentex E, Golfman L, Takeda S, Osada M, Dhalla NS.

Clin Exp Hypertens. 1999 Jan-Feb;21(1-2):145-56.

PMID:
10052650
19.

Transforming growth factor-beta function blocking prevents myocardial fibrosis and diastolic dysfunction in pressure-overloaded rats.

Kuwahara F, Kai H, Tokuda K, Kai M, Takeshita A, Egashira K, Imaizumi T.

Circulation. 2002 Jul 2;106(1):130-5.

20.

Effects of hydrochlorothiazide on cardiac remodeling in a rat model of myocardial infarction-induced congestive heart failure.

Luo J, Gao X, Peng L, Sun H, Dai G.

Eur J Pharmacol. 2011 Sep 30;667(1-3):314-21. doi: 10.1016/j.ejphar.2011.06.012. Epub 2011 Jun 17.

PMID:
21703256
Items per page

Supplemental Content

Write to the Help Desk